Author Index

Alfonso, L.A., 67
Anderson-Reitz, L., 154

Baker, C.R., 145
Barbera, F.N., 175
Barlow, A.R., 4
Beidler, S.M., 33
Boguniewicz, M., 48
Bourbonniere, A., 33

Chaffman, M.O., 95
Cole, C.F., 129
Coleman, C., 129
Cooper, D.M., 74
Crane, R., 145

Ellis, P., 87

Fowler, M.C., 204

Galvan, T.J., 185
Gary, A., 184, 195
Goldstein, M.K., 122

Hardwick, L., 175
Hertz, S.L., 154
Hogan, D.J., 67
Huebscher, R., 1, 43, 117, 181

Jacubowitz, T.R., 8
Johnson, C., 137
Johnson, D.P., 87
Jones, T., 213

Kaderman, R.A., 165
Kauffman, K.S., 4

Leber, K., 106

Matsen, Y., 195
Mechling, B.E., 154
Miller, V.G., 201

Naylor, L., 122
Nicol, N.H., 48

Pennypacker, H.S., 122
Perron, V.D., 106
Pozo-Kaderman, C., 165

Reavis, C., 208
Resnick, B., 12
Ridenour, N., 191
Romero, R., 159
Rudy, S.J., 56
Ryan, J.W., 27

Sander, A.A., 122
Shaughnessy, M., 3
Shaw, S.L.J., 120
Sinni-McKeehen, B., 47, 106

Toonkel, R., 165

Yurkow, J., 20

Subject Index

Abscess, breast, 142
Accessibility, to advanced practice nurses, 214
Acne, from topical corticosteroids, 102-103
Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
Acral lentiginous melanoma, 110
Actinic keratosis, as skin cancer precursor, 106-108
Adjuvant systemic therapy, for breast cancer, 149-150
Administrator, in advanced practice gerontologic rehabilitation program, 22-23
Adolescents, superficial fungal infections in, 56-66
Advanced practice
  access to, 214
  in geriatric rehabilitation, 20-26
Aerosols, corticosteroid, 98
Age, breast cancer adjustment and, 166
Aging. *See* Elderly persons
Aging in Place program, for care of frail elderly in rural communities, 33-38
AIDS. *See* Human immunodeficiency virus infection
Allergens, in atopic dermatitis, 49-50, 53
Allergic contact dermatitis, 69-72
Allergy, to topical corticosteroid preparations, 103-104
Alternative health practices. *See* NAC therapies
American College of Radiology, mammography reporting system, 130
American Diabetes Association, practice recommendations of, 201-203
American Holistic Nurses Association, 181-182
Anal cancer, in HIV infection, 91
Androgens, in benign breast disease, 142
Anemia, in hysterectomy recovery, 218
Angiogenesis, in wound healing, 78
Angular cheilitis, 61
  in HIV infection, 89
Anovulation, benign breast disease and, 138-139
Antibiotics, in atopic dermatitis, 52
Antihistamines, in atopic dermatitis, 52
Asteatotic eczema, 73
Athlete's foot, 60
Atopic dermatitis, 48-55
  allergens in, 49-50
  clinical characteristics of, 48-49
  immune abnormalities in, 49
  infections in, 50
  itch-scratch cycle and, 49
  treatment of
    conventional, 50-53
    novel, 54
    recalcitrant, 53-54
Atopic eczema, 72-73

Back injuries, treatment options for, 208-212
Bandages, stretch, for lymphedema, 162
Barriers, to health care, in outcome measurement, for developmentally disabled persons, 191
Bartonella infections, in HIV infection, 87-88
Basal cell carcinoma, 108-109
Baths, in atopic dermatitis, 50
Becaplermin, in wound healing, 85
Benign breast disease. *See* Breast disease, benign
Best practice network, in outcome determination, for developmentally disabled persons, 193
Biopsy, in breast disease, 143
  of sentinel lymph nodes, 148-149
Blood glucose control, in diabetes mellitus, recommendations for, 201-203
Blood pressure control, in women, 197
Body mass index, calculation of, 197
Bone loss, in women, 196
Bone marrow
  harvesting and replacement of, in high-dose therapy for breast cancer, 154-158
  suppression of, in chemotherapy, 151
Brachytherapy, for breast cancer, 149
Breast cancer
  advanced, psychosocial issues in, 171
  classification of, 146, 147

Breast cancer (*Continued*)
clinical examination for, 122-128
diagnosis of, 145
psychosocial issues in, 168
early stage, treatment of, 147-151
epidemiology of, 145
family history of, 167
imaging in, 129-136
inheritable, outcomes for, 204-207
Internet information on, 179
invasive, 147
locally advanced, treatment of, 151
lymph node involvement in, 148-149
metastatic
psychosocial issues in, 171
treatment of, 151-152
mortality in, 120-121
with high-dose therapy, 156-157
nipple discharge in, 141
noninvasive (carcinoma in situ), 147
prognostic factors in, 146
psychosocial aspects of, 165-174
recurrent
psychosocial issues in, 171
treatment of, 151-152
social support in, 167-168
staging of, 145-146
treatment of, 145-153
adjuvant systemic therapy in, 149-150
breast-conserving, 147-148, 168-169
chemotherapy in, 149-150, 152, 154-158, 169-170
classification of, 146
decision making in, 149
early stage, 147-151
follow-up care after, 152
goals of, 147
health problems after, 170-171
high-dose therapy for, 154-158
locally advanced, 151
lymphedema after, 159-164
metastatic, 151-152
psychosocial issues in, 165-174
radiation therapy in, 149-152, 169
reconstruction after, 147
recurrent, 151-152
research on, 175-179
side effects of, 150-151, 156-157, 169-170
surgical, 147-149, 151, 168-169
in terminal illness, 171
timing of, 150
Breast disease
benign, 137-144
abscess, 142
classification of, 139
clinical features of, 139-142
dominant lumps in, 140-141
epidemiology of, 137
hormonal influences on, 138-139
infections and inflammation, 141-142
in males, 143
mastalgia in, 139-140
mastitis, 141-142
Breast disease (*Continued*)
nipple discharge in, 141
nodularity of, 139
physiologic features of, 139
risk factors for, 137-138
treatment of, 142-143
biopsy in, 143
examination for, 122-128
after breast cancer treatment, 152
learning techniques for, 122-126
5Ps mnemonic for, 126-127
self-examination, 122-123
sensitivity and specificity of, 123-124
time allocation for, 125-126
imaging in, 129-136
malignant. *See* Breast cancer

Caffeine, avoidance of, in benign breast disease, 142
Calendar of events, 217
Cancer
breast. *See* Breast cancer
in HIV infection, 91
skin, 106-112
melanoma, 91, 109-111
nonmelanoma, 108-109
premalignant neoplasms and, 107-108
Candidiasis, 61
diagnosis of, 57-58
in HIV infection, 89-90
microbiology of, 56-57
treatment of, 61-65
Carcinoma
basal cell, 108-109
in HIV infection, 91
squamous cell, of skin, 108-109
Cardiovascular disease, in women, 197
Care manager
in advanced practice gerontologic rehabilitation program, 23-24
in EverCare program for nursing home medical care, 30
Care plan, for elderly persons, culturally sensitive, 10-11
CARE (Collaborative Assessment and Rehabilitation for Elders) Program, 20-26
Cat-scratch disease, in HIV infection, 87-88
Cervical cancer, in HIV infection, 91
Cheerleader, in EverCare program for nursing home medical care, 32
Cheilitis, angular, 61
in HIV infection, 89
Chemicals, irritation from, in atopic dermatitis, 52-53
Chemoattraction, in wound healing, 77-78
Chemotherapy
for actinic keratosis, 108
for breast cancer, 149-150, 152
high-dose, 154-158
psychosocial issues in, 169-170
Chickenpox, in HIV infection, 88-89
Children. *See* Pediatric patients
Clinical Management System software, for congestive heart failure, 218-219
Clinical preventive services, in outcome determination, for developmentally disabled persons, 193

Clinical trials, on breast cancer treatment, 175-179
  achievements of, 178-179
  decision to participate in, 175-177
  informed consent for, 177-178
  nature of, 177
  phases of, 176-177
Clinical work, in lifecare community-faculty practice integration, 13
Clinician, in EverCare program for nursing home medical care, 30
Coach/educator, in EverCare program for nursing home medical care, 30-31
Coccidioidomycosis, in HIV infection, 90
Cochrane Collaboration, in outcome determination, for developmentally disabled persons, 193
Cognitive dysfunction, in chemotherapy, 170
Collaborative Assessment and Rehabilitation for Elders Program, 20-26
Collaborator, in EverCare program for nursing home medical care, 30
Collagen, synthesis of, in wound healing, 78, 81-83
Collagenase, in wound healing, 83
Communicator, in EverCare program for nursing home medical care, 31-32
Complementary health practices. *See* NAC therapies
Complex decongestive therapy, for lymphedema, 162
Comprehensive Outpatient Rehabilitation Facility, Collaborative Assessment and Rehabilitation for Elders Program certified as, 20-26
Compression garments, for lymphedema, 162, 163
Congestive heart failure
  management software program for, 218-219
  in women, 198-199
Connective tissue, topical corticosteroid effects on, 102
Consultant, in advanced practice gerontologic rehabilitation program, 25
Contact dermatitis, 67-73
  allergic, 69-72
  differential diagnosis of, 72-73
  irritant, 67-69
Continuing care retirement community, faculty practice with, 12-19
Coordinator, in EverCare program for nursing home medical care, 30
Coping style, breast cancer adjustment and, 166-167
Coronary artery disease, in women, 197
Corticosteroids, topical, 95-105
  application of, 99-100
  in atopic dermatitis, 51-52
  in contact dermatitis, 72
  in elderly persons, 101
  failure of, 101-102
  generic, 99
  hydration with, 100
  indications for, 96-97
  occlusion with, 100-101
  in pediatric patients, 101
  potency of, 96-99
  preparations for, 95, 98-99
  rebound phenomenon with, 101
  side effects of, 102-104
  tachyphylaxis with, 101
Counselor, in EverCare program for nursing home medical care, 31
Creams
  corticosteroid, 95
  moisturizing, in atopic dermatitis, 50-51
Cryotherapy, for actinic keratosis, 108
Cryptococcosis, in HIV infection, 90
Culturally sensitive care, for elderly, 8-11
Culture, fungal, in superficial infections, 58
Cyclosporin, in atopic dermatitis, 54
Cysts, breast, 140-141
Cytokines
  in atopic dermatitis, 49
  in wound healing, 79-80, 82
    proinflammatory, 82-83

Danazol, in benign breast disease, 142
Data collection, for outcome measurement, 187, 188
Debridement, of chronic wounds, 84-85
Decongestive therapy, complex, for lymphedema, 162
Deinstitutionalization, of developmentally disabled persons, 192
Dermatitis
  atopic, 48-55
  contact, 67-73
  seborrheic, in HIV infection, 92
Dermatology
  atopic dermatitis, 48-55
  contact dermatitis, 67-73
  fungal infections, in pediatric patients, 56-66
  in HIV infection, 87-94
  skin cancer, 106-112
  topical corticosteroids, 95-105
  wound healing, 74-86
Dermatophytosis, 56-58
  diagnosis of, 57-58
  microbiology of, 56
  treatment of, 61-65
Detergents, irritation from, in atopic dermatitis, 52-53
Developmental disability, realistic outcomes for, 191-194
Diabetes mellitus
  chronic wounds in, 84
  outcomes in, 201-203
  in women, 198-199
Diaper rash, 61
Diet, in obesity, 197
Digital mammography, 131-132
Disability, developmental, realistic outcomes for, 191-194
Diuretics, in lymphedema, 162
Dominant lumps, in benign breast disease, 140-141
Dressings, for topical corticosteroids, 100-101
Drug reactions, in HIV infection, 92-93
Dust mite allergy, atopic dermatitis in, 53

Eczema, differential diagnosis of, 48-49, 72-73
Edema, of lymph nodes. *See* Lymphedema
Education
  nursing
    on health promotion, 215
    lifecare community care integration with, 12-19
  patient
    on atopic dermatitis, 53

Education (*Continued*)
on back injury treatment, 209
on diabetes mellitus control, 201-203
on lymphedema, 162-163
Educator, in EverCare program for nursing home medical care, 30-31
Elastography, of breast, 133-134
Elderly persons
care of
culturally sensitive, 8-11
frail, EverCare program for, 27-32
in lifecare community, faculty practice with, 12-19
in nursing homes, 27-32
population-focused, 4-7
in rehabilitation, 20-26
rural community-based, 33-38
women, 195-200
topical corticosteroids for, 101
Emotional stress, reduction of, in atopic dermatitis, 53
Employment, back injuries in, outcomes for, 208-212
Endothelial cells, proliferation of, in wound healing, 81
Environmental factors
in atopic dermatitis, 52-53
in contact dermatitis, 67
Eosinophilic folliculitis, in HIV infection, 92
Epidermal growth factor, in wound healing, 79, 81
Epstein-Barr virus infections, in HIV infection, 89
Esophagus, candidiasis of, in HIV infection, 89
Estrogen, benign breast disease and, 138-139
Ethical issues, in genetic testing, 205
Ethnic factors, in breast cancer adjustment, 165-166
Evening primrose oil, in benign breast disease, 142
EverCare program, for medical care in nursing homes, 27-32
Evidence-based practice, in outcome determination, for developmentally disabled persons, 193
Examination, clinical, of breast. *See* Breast disease, examination for
Exercise
in back injury, 209
in diabetes mellitus, 203
in lymphedema, 163
in obesity, 197
Extracellular matrix, in wound healing, 81

Familial atypical mole-melanoma syndrome, 109
Family, breast cancer impact on, 171-172
Fatigue, in hysterectomy recovery, 218
Fibroadenoma, of breast, 140-141
Fibroblast growth factor, in wound healing, 79-81
Fibroblasts, in wound healing, 78, 81
Fibronectin, in wound healing, 83
Fine needle aspiration, in breast disease, 143
Finn chamber, for patch testing, in allergic contact dermatitis, 70
Fluconazole, in fungal infections, 64
Folliculitis
in HIV infection, 87, 92
Pityrosporum, 60-61
Food allergy, atopic dermatitis in, 53
Foot, tinea infections of, 60

Fractures, in osteoporosis, 196
Fungal infections
in HIV infection, 89-90
superficial, 56-66
candidiasis, 61
dermatophytosis, 58-60
diagnosis of, 57-58
microbiology of, 56-57
pityriasis, 60-61
treatment of, 61-65

Galactoceles, 140-141
Galactorrhea, 141
Gamolenic acid, in benign breast disease, 142
Gels, corticosteroid, 95
Genetic testing, for breast cancer, 204-207
Geriatric nurse practice. *See* Elderly persons, care of
Glaucoma, from topical corticosteroids, 104
Glucose
control of, in diabetes mellitus, recommendations for, 201-203
intolerance of, in syndrome X, 197
Griseofulvin, in fungal infections, 63
Groin, tinea infections of, 59
Growth factors, in wound healing, 77-83, 85
Gynecomastia, 143

Hair
growth of, topical corticosteroid effects on, 103
loss of, in chemotherapy, 169
Hairy leukoplakia, in HIV infection, 89
Head, tinea infections of, 59
Healing. *See* Wound healing
Health, as social issue, 5-6
Health care, access to, for elderly, 8-9
Health promotion
change and, 214
commitment to, 215-216
in lifecare community, 13-14
nursing education for, 215
strategies for, 214-215
Healthy People 2000 goals, related to menopausal or postmenopausal women, 195-196
Heart failure
congestive, in women, 198-199
management software program for, 218-219
Hemoglobin A1c measurement, in diabetes mellitus, 201
Herpes simplex virus infections, in HIV infection, 89
Histoplasmosis, in HIV infection, 90
HIV infection. *See* Human immunodeficiency virus infection
Holistic nursing, 181-183
outcomes and, 213-214
Hormones
benign breast disease and, 138-139
in breast cancer, 150, 152
in gynecomastia, 143
Hot flashes, in chemotherapy, 170
Human Genome Project, 205-206
Human immunodeficiency virus infection, dermatologic complications in, 87-94
assessment of, 87

Human immunodeficiency virus infection, dermatologic complications in (*Continued*)
bacterial infections, 87-88
drug reactions, 92-93
folliculitis, 92
fungal infections, 89-90
malignant, 91
papulosquamous, 92
parasitic diseases, 90-91
viral infections, 88-89
Hydration
in atopic dermatitis, 50
with topical corticosteroids, 100
Hyperglycemia, control of, recommendations for, 201-203
Hypertension, in women, 197
Hypothalamus-pituitary-adrenal axis, suppression of, from topical corticosteroids, 103
Hysterectomy, recovery from, 218

Imaging, breast. *See also* Mammography
critical factors in, 130
elastography in, 133-134
information sources for, 134-135
magnetic resonance imaging in, 132
nurse practitioner role in, 134
positron emission tomography in, 133
radionuclide studies in, 132-134
technetium 99m studies in, 132-133
Immigrant population, elderly, culturally sensitive care for, 8-11
Immune system, disorders of, atopic dermatitis and, 49, 54
Industrial back injuries, outcomes for, 208-212
Infections
in atopic dermatitis, 50
breast, 141-142
from topical corticosteroids, 103
Inflammation, breast, 141-142
Inflammatory phase, of wound healing, 76-81
Informed consent, for clinical trials, on breast cancer treatment, 177-178
Insomnia, interventions for, 117-119
Institutional issues, in outcome measurement, for developmentally disabled persons, 192
Insulin, resistance to, in syndrome X, 197
Insulin-like growth factor, in wound healing, 79, 81
Interleukin(s), in wound healing, 82-83
Internet, breast cancer information on, 179
Irritable bowel syndrome, in women, impact of, 219-220
Irritant contact dermatitis, 67-69
Irritants, identification of, in atopic dermatitis, 52-53
Itch-scratch cycle, in atopic dermatitis, 49
Itraconazole, in fungal infections, 64

Jock itch, 59

Kaposi's sarcoma, in HIV infection, 91
Keratosis, actinic, as skin cancer precursor, 106-108
Kerions, 59
Ketoconazole, in fungal infections, 63-64
KOH (potassium hydroxide) test, in fungal infections, 57-58

Lactation, breast disorders in, 141-142
Latex allergy, 72
Leishmaniasis, in HIV infection, 90
Lentigo maligna melanoma, 110
Life stage, breast cancer adjustment and, 166
Lifecare community, faculty practice with, 12-19
balance among components in, 17-18
clinical work in, 13
health promotion projects in, 13-14
partnership development for, 12-13
research in, 14-15
teaching in, 15-17
Lotions
corticosteroid, 98
moisturizing, in atopic dermatitis, 50-51
Lumps, dominant, in benign breast disease, 140-141
Lymph nodes, breast cancer spread to, 148-149
Lymphedema, after breast cancer treatment, 159-164
anatomy of, 159
assessment of, 160-162
diagnosis of, 160
fluid dynamics of, 159-160
interventions for, 162
patient education on, 162-163
physiology of, 159
stages of, 160
subclinical, 160
Lymphoma, in HIV infection, 91

Macrophages, in wound healing, 80
Magnetic resonance imaging, of breast, 132
Malassezia infections, 60-61
Malignant melanoma, 109-111
in HIV infection, 91
MammaCare technique, for breast examination, 123, 125
Mammaplasia, 143
Mammography, 129-136
American College of Radiology reporting system, 130
after breast cancer treatment, 152
critical factors in, 130
current status of, 129-130
digital, 131-132
history of, 129
information sources for, 134-135
Manual lymph drainage, in lymphedema, 162
Massage, 1
Mastalgia, in benign breast disease, 139-140
Mastectomy
in breast cancer, 147-149, 151
psychosocial issues in, 168-169
lymphedema after, 159-164
Mastitis, 141-142
Matrix metalloproteinases, in wound healing, 80-83
Maturation phase, of wound healing, 81-82
Medicare, Collaborative Assessment and Rehabilitation for Elders Program reimbursement under, 21
Melanoma, malignant, 109-111
in HIV infection, 91
Menopause, premature, in chemotherapy, 170
Mental health care, in breast cancer, 172
Meta-analysis, in outcome determination, for developmentally disabled persons, 192-193

Metalloproteinases, matrix, in wound healing, 80-83
Metastasis, from breast cancer
  psychosocial issues in, 171
  treatment of, 151-152
Microscopy, in fungal infections, 57-58
Minorities, elderly, culturally sensitive care for, 8-11
Mitogenesis, in wound healing, 78
Moisturizers, in atopic dermatitis, 50-51
Molluscum contagiosum, in HIV infection, 89
Monocytes, in wound healing, 80
Multidisciplinary environment, outcome measurement in, 187-189
Mycobacterium avium intracellulare infections, in HIV infection, 88
Myelosuppression, in chemotherapy, 151
Myocardial infarction, in women, 197

NAC therapies
  holistic nursing, 181-183
  massage, 1-2
  sleep promotion, 117-119
  therapeutic touch, 43-46
Nails
  melanoma of, 110
  tinea infections of, 60
National Eczema Association for Science and Education, 53, 54
Natural health practices. *See* NAC therapies
Nausea and vomiting, in chemotherapy, 169-170
Neovascularization, in wound healing, 78
Neuropathy, chronic wounds in, 84
Neutrophils, in wound healing, 77-78
Nipple discharge, in benign breast disease, 141
Nodularity, in benign breast disease, 139
Nurse specialist, in advanced practice gerontologic rehabilitation program, 24-25
Nursing homes, medical care in, EverCare experience, 27-32
Nystatin, in fungal infections, 62

Obesity, in women, 198
Occlusion
  in atopic dermatitis, 50-51
  with topical corticosteroids, 100-101
Occupational disorders
  back injuries, outcomes for, 208-212
  contact dermatitis, 69
Ointments
  corticosteroid, 95, 98
  moisturizing, in atopic dermatitis, 50-51
Onychomycosis, 60
Ophthalmologic examination, in diabetes mellitus, 203
Oral contraceptives, benign breast disease and, 138, 142
Osteoporosis, 196
Outcomes
  for back injuries, 208-212
  in care management, 185
  data analysis for, 188-189
  for developmental disability, 191-194
  in diabetes mellitus, 201-203
  identifying, 185-190
  for inheritable breast cancer, 204-207
Outcomes (*Continued*)
  measurement of
    agency-oriented, 188
    data collection for, 187, 188
    instruments for, 187, 188
    methods for, 186-187
    in multidisciplinary environment, 187-189
    patient-oriented, 188
    perils of, 189
    profession-oriented, 188
    resource requirements for, 189
  negative, 185-186
  positive, 185-186
    future directions for, 213-216
  variables of, 186-187
Oxygen therapy, for chronic wounds, 85

PACE (Program of All-inclusive Care for the Elderly), 33-34
Pain, in benign breast disease, 139-140
Papular mucinosis, in HIV infection, 92
Papulosquamous disorders, in HIV infection, 92
Parasitic diseases, in HIV infection, 90-91
Parental issues, in outcome measurement, for developmentally disabled persons, 191
Patch testing, in allergic contact dermatitis, 70-72
Pediatric patients
  superficial fungal infections in, 56-66
  topical corticosteroids for, 101
Peliosis, in HIV infection, 87-88
Penicilliosis, in HIV infection, 90
Penn Nursing Network, advanced practice geriatric rehabilitation program of, 20-26
Perfusion, increase of, for chronic wounds, 85
Peripheral blood progenitor cells, in high-dose therapy for breast cancer, 154-158
Personality, breast cancer adjustment and, 166-167
Petroleum jelly, in atopic dermatitis, 50-51
Pfizer Health Solutions Clinical Management System software, for congestive heart failure, 218-219
Phagocytosis, in wound healing, 80
Photochemotherapy, for atopic dermatitis, 54
Physical examination, of elderly persons, cultural sensitivity in, 10
Pityriasis
  diagnosis of, 57-58
  microbiology of, 56
  treatment of, 61-65
Pityriasis rubra pilaris, in HIV infection, 92
Platelet-derived growth factor, in wound healing, 79, 81
Platelets, in wound healing, 77
Pneumocystis carinii infections, in HIV infection, 91
Pneumonia
  in nursing homes, management in EverCare program, 29
  Pneumocystis carinii, in HIV infection, 91
Population-focused care, of elderly persons, 4-7
Positron emission tomography, of breast, 133
Potassium hydroxide (KOH) test, in fungal infections, 57-58
Pressure ulcers, healing of, 85

Preventive services, in outcome determination, for developmentally disabled persons, 193
Primary care, definition of, 5, 6
Primary care practice network, in outcome determination, for developmentally disabled persons, 193-194
Progenitor cells, in high-dose therapy for breast cancer, 154-158
Program of All-inclusive Care for the Elderly, 33-34
Prolactin, benign breast disease and, 138, 140-141
Proliferative phase, of wound healing, 81
Prostaglandin E2, in benign breast disease, 142
Pruritus, in atopic dermatitis, 49
Psoralen with ultraviolet light, for atopic dermatitis, 54
Psoriasis, in HIV infection, 92
Psychiatric care, in advanced practice gerontologic rehabilitation program, 24-25
Psychosocial aspects, of adjustment to breast cancer, 165-174
  family considerations, 171-172
  medical variables, 168-171
  mental health referrals, 172
  patient variables, 166-168
  sociocultural variables, 165-166
PUVA (psoralen with ultraviolet light), for atopic dermatitis, 54

Quality of life, in diabetes mellitus, 202

Racial factors, in breast cancer adjustment, 165-166
Radiation therapy, for breast cancer, 149-152, 169
Radionuclide studies, of breast, 132-133
Rebound phenomenon, in corticosteroid therapy, 101
Regranex growth factor, in wound healing, 85
Rehabilitation, geriatric, advanced practice role in, 20-26
Religion, therapeutic touch and, 44-45
Research
  on breast cancer treatment, 175-179
  in lifecare community, 14-15
Resources, for outcome measurement, 189
Retirement community, faculty practice with, 12-19
Roland Park Place lifecare community, faculty practice with, 12-19
Rural communities, care of frail elderly in, 33-38

Sarcoma, Kaposi's, in HIV infection, 91
Scalp, tinea infections of, 59
Seborrheic dermatitis, in HIV infection, 92
Selenium sulfide shampoos, in fungal infections, 65
Senile keratosis, as skin cancer precursor, 106-108
Sentinel lymph node biopsy, in breast cancer, 148-149
Sex hormones
  benign breast disease and, 138-139
  in gynecomastia, 143
Sexual dysfunction, in breast cancer, 170
Shampoos, selenium sulfide, in fungal infections, 65
Sigma Theta Tau, International, primary care practice network of, 193-194
Skin disorders. *See* Dermatology
Skin tests, for allergy
  in atopic dermatitis, 53
  in contact dermatitis, 70-72
Sleep promotion, 117-119
Soap, irritation from, in atopic dermatitis, 52-53
Social issues, in outcome measurement, for developmentally disabled persons, 191-192
Social support, in breast cancer, 167-168
Sociocultural variables, in breast cancer adjustment, 165-166
Solar keratosis, as skin cancer precursor, 106-108
Squamous cell carcinoma, of skin, 108-109
Staging, of breast cancer, 145-146
Staphylococcus aureus infections
  in atopic dermatitis, 50
  in HIV infection, 87
Stereotactic biopsy, in breast disease, 143
Stereotypes, cultural, 9-10
Stress reduction, in atopic dermatitis, 53
Stroke
  in syndrome X, 197
  in women, 197-198
Sunlight, skin damage from, cancer development and, 106-109
Surgery, in breast cancer, 147-149, 151
  psychosocial issues in, 168-169
Swedish massage, 1
Swelling, of lymph nodes. *See* Lymphedema
Syndrome X, in women, 198
Syphilis, in HIV infection, 88

T lymphocytes, in atopic dermatitis, 49
Tachyphylaxis, in corticosteroid therapy, 101
Tacrolimus, in atopic dermatitis, 54
Tamoxifen, in breast cancer, 150, 152
Tar preparations, in atopic dermatitis, 52
Teaching program, lifecare community care integration with, 12-19
Technetium 99m studies, of breast, 132-133
Terbinafine, in fungal infections, 64-65
Therapeutic touch, 43-46
Thin layer rapid use epicutaneous test, in allergic contact dermatitis, 70
Thrush, 61
  in HIV infection, 89
Tinea infections, 56-58
Tissue inhibitors of metalloproteinases, in wound healing, 81-83
Touch, therapeutic, 43-46
Transforming growth factor-, in wound healing, 79-81
Trastuzumab, in breast cancer, 152
TRUE (thin layer rapid use epicutaneous) test, in allergic contact dermatitis, 70-71
Tuberculosis, in HIV infection, 88
Tumor necrosis factor, in wound healing, 79-80, 82-83

Ulcers, pressure, healing of, 85
Ultraviolet light
  skin damage from, cancer development and, 106-109
  therapeutic, for atopic dermatitis, 54
University of Maryland, School of Nursing, lifecare community care integration with, 12-19
University of Pennsylvania, advanced practice geriatric rehabilitation program of, 20-26
Urticaria, contact, 71-72

Varicella-zoster virus infections, in HIV infection, 88-89
Viral infections, in HIV infection, 88-89
Vomiting, in chemotherapy, 169-170
Vulvovaginal candidiasis, 61
  in HIV infection, 89

Wet wrap therapy, for atopic dermatitis, 53-54
Witchcraft, therapeutic touch and, 44-45
Women
  irritable bowel syndrome in, impact of, 219-220
  menopausal and postmenopausal
    advanced practice nurse role in, 199-200
    cardiovascular disease in, 197
    congestive heart failure in, 199
    diabetes mellitus in, 198-199
    Healthy People 2000 goals for, 195-196
    hypertension in, 197
    obesity in, 198
    osteoporosis in, 196
Women (*Continued*)
    stroke in, 197-198
    syndrome X in, 198
Wood's lamp, in fungal infections, 58
Work-related back injuries, outcomes for, 208-212
Wound healing, 74-86
  of acute wound, 75
  of chronic wound, 75, 82-84
  definition of, 75-76
  failure of, 82-84
  methods facilitating, 84-85
  phases of, 76-82
    inflammatory, 76-81
    maturation, 81-82
    proliferative, 81
  wound terminology and, 74-75

Xerotic eczema, 73